Latest Contract Research Organisations News

Page 1 of 6
The US FDA has refused to lift the clinical hold on Argenica Therapeutics’ xaranetide stroke program, demanding a GLP rat neurotoxicity study and imposing a lower exposure limit than the company proposed for Phase 2b. Argenica plans to challenge parts of the assessment while pursuing regulatory submissions elsewhere.
Ada Torres
Ada Torres
19 Nov 2026
Racura Oncology has cleared a key ethics hurdle for its pivotal EMILI trial of RC220 in relapsed or refractory acute myeloid leukaemia. The Phase 2b program is funded from existing cash, but efficacy, regulatory and funding tests still stand between the company and Phase 3.
Ada Torres
Ada Torres
18 Nov 2026
Charles River Laboratories will pay about US$470 million in cash for Frontage’s bioanalysis and DMPK operations in Pennsylvania, with a further US$75 million tied to performance. The proposed acquisition expands Charles River’s clinical testing capabilities but will initially be neutral to non-GAAP earnings per share.
Ada Torres
Ada Torres
9 Nov 2026
Radiopharm Theranostics has reached final alignment with the U.S. FDA on a single pivotal Phase 3 trial for RAD101, its brain metastases imaging agent. The approximately 280-patient study is expected to begin dosing in the first half of 2027, moving the program from regulatory planning towards execution.
Ada Torres
Ada Torres
4 Nov 2026
Pathkey.AI has secured its first Chipforge customer contract ahead of the semiconductor platform’s commercial release, while a $2.8 million placement lifted quarter-end cash to $5.83 million. The company remains early-stage, with just $10,000 in customer receipts during the September quarter and further commercial conversion still to prove.
Sophie Babbage
Sophie Babbage
30 Oct 2026
Cambium Bio has moved Elate Ocular into Phase 3 manufacturing and submitted an updated CAMOMILE-2 protocol to the FDA. The company is targeting First Patient In by year-end, but that timetable depends on a conditional A$7.1 million placement, unsigned CRO agreements and release of the first clinical batch.
Ada Torres
Ada Torres
28 Oct 2026
Compumedics Limited (ASX:CMP) returned to profit in FY26 as record revenue, stronger cash generation and a sharp rise in MEG and SaaS sales reshaped its earnings profile. The company enters FY27 with A$28.3 million of open orders, but lower gross margins and uneven US and European execution remain key tests.
Victor Sage
Victor Sage
30 Sept 2026
Imagion Biosystems has signed key CRO work orders and completed manufacturing of its MagSense HER2 Imaging Agent, advancing its Phase 1b/2 clinical trial targeting HER2+ breast cancer. Trial initiation is underway with seven prospective sites, including contract talks with the first US clinical site.
Ada Torres
Ada Torres
26 Aug 2026
Genetic Signatures narrowed its FY2026 net loss by 30% to $14 million amid a strategic overhaul, signing a key 10-year supply deal with Denmark’s Hvidovre Hospital and resetting its US market approach.
Ada Torres
Ada Torres
25 Aug 2026
EVE Health Group has progressed its Libbo pilot clinical study for erectile dysfunction with dosing set for Q4 2026 and achieved a major solubility breakthrough for apixaban, while appointing Ben Rohr as CEO to drive commercial growth.
Ada Torres
Ada Torres
7 Aug 2026
Genetic Signatures has completed a major restructure delivering $5 million in annual savings from FY2027 and secured a decade-long supply contract with Denmark’s Hvidovre Hospital, while posting $14.8 million revenue for FY2026 amid market pressures.
Ada Torres
Ada Torres
23 July 2026
CONNEQT Health's June quarter saw record consumer revenue growth and a 70% jump in enterprise subscription ARR, supported by a $5.5 million placement and progress on its FDA regulatory pathway for its cloud-based vascular analytics platform.
Ada Torres
Ada Torres
21 July 2026

Browse the archive

Full archive